The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications.

Cortese S, McGinn K, Højlund M, Apter A, Arango C, Baeza I, Banaschewski T, Buitelaar J, Castro-Fornieles J, Coghill D, Cohen D, Grünblatt E, Hoekstra PJ, James A, Jeppesen P, Nagy P, Pagsberg AK, Parellada M, Persico AM, Purper-Ouakil D, Roessner V, Santosh P, Simonoff E, Stevanovic D, Stringaris A, Vitiello B, Walitza S, Weizman A, Wohlfarth T, Wong ICK, Zalsman G, Zuddas A, Moreno C, Solmi M, Correll CU

Open source

DOI
10.1016/j.neubiorev.2023.105149
Published
2023 Jun
Container
Neuroscience and biobehavioral reviews
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.neubiorev.2023.105149,
  title = {The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications.},
  author = {Cortese S and McGinn K and Højlund M and Apter A and Arango C and Baeza I and Banaschewski T and Buitelaar J and Castro-Fornieles J and Coghill D and Cohen D and Grünblatt E and Hoekstra PJ and James A and Jeppesen P and Nagy P and Pagsberg AK and Parellada M and Persico AM and Purper-Ouakil D and Roessner V and Santosh P and Simonoff E and Stevanovic D and Stringaris A and Vitiello B and Walitza S and Weizman A and Wohlfarth T and Wong ICK and Zalsman G and Zuddas A and Moreno C and Solmi M and Correll CU},
  year = {2023},
  journal = {Neuroscience and biobehavioral reviews},
  doi = {10.1016/j.neubiorev.2023.105149},
  url = {https://doi.org/10.1016/j.neubiorev.2023.105149}
}

RIS

TY  - JOUR
TI  - The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications.
AU  - Cortese S
AU  - McGinn K
AU  - Højlund M
AU  - Apter A
AU  - Arango C
AU  - Baeza I
AU  - Banaschewski T
AU  - Buitelaar J
AU  - Castro-Fornieles J
AU  - Coghill D
AU  - Cohen D
AU  - Grünblatt E
AU  - Hoekstra PJ
AU  - James A
AU  - Jeppesen P
AU  - Nagy P
AU  - Pagsberg AK
AU  - Parellada M
AU  - Persico AM
AU  - Purper-Ouakil D
AU  - Roessner V
AU  - Santosh P
AU  - Simonoff E
AU  - Stevanovic D
AU  - Stringaris A
AU  - Vitiello B
AU  - Walitza S
AU  - Weizman A
AU  - Wohlfarth T
AU  - Wong ICK
AU  - Zalsman G
AU  - Zuddas A
AU  - Moreno C
AU  - Solmi M
AU  - Correll CU
PY  - 2023
JO  - Neuroscience and biobehavioral reviews
DO  - 10.1016/j.neubiorev.2023.105149
UR  - https://doi.org/10.1016/j.neubiorev.2023.105149
ER  - 

APA

S, C., K, M., M, H., A, A., C, A., I, B., T, B., J, B., J, C., D, C., D, C., E, G., PJ, H., A, J., P, J., P, N., AK, P., M, P., AM, P., D, P., V, R., P, S., E, S., D, S., A, S., B, V., S, W., A, W., T, W., ICK, W., G, Z., A, Z., C, M., M, S., & CU, C. (2023). The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications.. Neuroscience and biobehavioral reviews. https://doi.org/10.1016/j.neubiorev.2023.105149

Source records